Category Press Releases

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

Vivani Medical, Inc. (Nasdaq: VANI), a pioneering biopharmaceutical company in the preclinical stage, has recently announced a significant move towards advancing its innovative long-term drug implants. In a registered direct offering, the company has entered into a securities purchase agreement…

Read MoreVivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition (Long COVID)

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi and Osaka University (Location: Suita, Osaka, President: Shojiro Nishio) have established a joint research laboratory (research lab’s name: Joint Research Laboratory…

Read MoreShionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition (Long COVID)

FDA Prioritizes Review of EPKINLY® for Tough Follicular Lymphoma Cases

AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody. This treatment targets adult patients with relapsed…

Read MoreFDA Prioritizes Review of EPKINLY® for Tough Follicular Lymphoma Cases

FDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets its use as an add-on maintenance treatment for specific adult…

Read MoreFDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils 2024 Grant Initiative to Empower Female Entrepreneurs

Today, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has officially launched the application process for its 2024 BOTOX® Cosmetic grant program, aimed at supporting women entrepreneurs. Following a successful partnership with IFundWomen in 2023, this year marks the second…

Read MoreBOTOX® Cosmetic (onabotulinumtoxinA) Unveils 2024 Grant Initiative to Empower Female Entrepreneurs

Argenx’s VYVGART Hytrulo Receives FDA Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the well-being of individuals with severe autoimmune conditions, has announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA)…

Read MoreArgenx’s VYVGART Hytrulo Receives FDA Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) revealed today that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its experimental drug olezarsen. This designation is specifically for the treatment of familial chylomicronemia syndrome (FCS), a…

Read MoreOlezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome